Everest Medicines Limited has entered into an exclusive agreement with Australia-listed Dimerix Limited on 16 June 2026 to develop and commercialize the Phase 3 small-molecule CCR2 inhibitor DMX-200 for focal segmental glomerulosclerosis (FSGS) across Greater China, South Korea and select Southeast Asian markets.

Key financial terms • Upfront payment: US$10.00 million. • Development and regulatory milestones: up to US$30.00 million. • Sales-based milestones: up to US$300.00 million. • Tiered royalties: 10%–15% on future annual net sales within the licensed territories.

Strategic rationale The transaction adds a late-stage nephrology asset with orphan-drug designations from both the U.S. FDA and the EMA to Everest Medicines’ kidney and autoimmune disease portfolio, enhancing pipeline depth and regional market positioning.

Regulatory and listing implications With the highest applicable percentage ratio below 5%, the deal is classified as a small transaction under Chapter 14 of the Hong Kong Listing Rules and is exempt from reporting, announcement and shareholder approval requirements.